Abstract
The aim of the work — is to investigate the effect of the combined use of erythropoietin (EPO) and laser radiation (LR) on the morphometric features of the expression of vascular endothelial growth factor (VEGF) and neoangiogenesis in experimental cerebral cortex ischemia (ICGM). Materials and methods of research. The work was performed on 120 white nonlinear rats. ICGM was created by diathermocoagulation of pial vessels in the sensorimotor zone. EPO was applied intraperitoneally at a total dose of 15,000 IU/kg, laser radiation was applied once to the area of the ischemic focus (970 nm, 2 min). The study used histological (staining of sections with hematoxylin and eosin and according to the method of M. Bilshovsky), immunohistochemical (determining the expression of VEGF), morphometric (the number of cells with VEGF expression, the number of small blood vessels were counted, the infarction area was measured), statistical methods of research. The results of the study. The obtained results indicate that the mechanism of the neuroprotective action of EPO is an improvement in microcirculation due to an increase in the number of small blood vessels, and the effect of LR leads to an increase in both the number of blood vessels and an increase in the expression of VEGF in the lesion. Conclusions. 1. During experimental ICGM in rats, the expression of VEGF in the lesion increases and the number of small blood vessels decreases on the 3rd, 7th, 14th, and 30th days of the experiment. 2. Systemic use of EPO in an experimental ICGM at a total dose of 15,000 IU/kg leads to an increase in the number of small blood vessels, and local exposure to the area of LR ischemia leads to an increase in the expression of VEGF and the number of small blood vessels on the 3rd, 7th, 14th, 30th day of the experiment; the representation of blood vessels is higher after exposure to LR compared with the use of EPO. 3. The maximum expression of VEGF and the number of small blood vessels in experimental ICGM were detected after the combined use of EPO and LR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.